How an enzyme protects the colon
Lipid homeostasis is essential for a person to lead a normal life, and when the human body is unable to regulate lipid metabolism when it is subject to diseases such as metabolic syndromes, inflammation and cancer.

In lipid metabolism, the enzyme stearoyl-CoA desaturase, or SCD, catalyzes the introduction of a 9-cis double bond into saturated acyl chains of palmitoyl-CoA or stearoyl-CoA to produce their monounsaturated forms. These molecules play crucial roles in the synthesis of various tissue lipids.
Expression of SCD is tissue-specific, and while it has been extensively studied in lipogenic tissues, researchers do not yet fully understand its role in the intestines, which are exposed to dietary fatty acids. Recent research shows how intestinal SCD protects against acute colonic inflammation and tissue damage.
Camille Duchamp, a grad student in at Rutgers University, and colleagues studied the impact of intestinal SCD on dextran sulfate sodium–induced colitis using mice that had been genetically altered to lack two of the enzyme’s isoforms, SCD1 and SCD2.
“We hypothesize that endogenously synthesized fatty acids may be channeled differentially than those obtained from the diet or circulation,” Duchamp wrote in an email, “such that the absence of the protein that catalyzes their synthesis has acute and profound consequences on cellular and organ health.”
The team assessed fecal blood, weight fluctuations and cytokine levels, and did histological analyses to determine SCD’s influence on disease severity. They saw elevated levels of the protein lipocalin-2, or LCN2, produced by neutrophils, macrophages and intestinal epithelial cells, in the altered mice, indicating a severe colitis phenotype.

The lab’s previous studies showed that mice lacking just SCD1 had reduced alpha diversity in their intestinal microbiome, a characteristic associated with Crohn’s disease and ulcerative colitis. However, Duchamp noted that deleting SCD1 alone may not significantly impact colitis development, perhaps because SCD2 compensates. By continuing to study the gut microbiome of mice lacking both isoforms, the researchers aim to find potential associations with the increased colonic inflammation in these animals.
Duchamp’s team also found that supplementing the diets of the mice lacking both SCD1 and SCD 2 with monounsaturated oleic acid alleviated colonic inflammation, demonstrating the significance of intestinal lipid composition in health and disease. Despite ample dietary and circulating lipid sources, the mice needed renewed synthesis of monounsaturated fatty acid, or MUFA.
In the lab’s published research, mice lacking intestinal SCD1 exhibited reduced levels of myristoleic acid, an unsaturated fatty acid, prompting speculation that mice lacking both SCD1 and SCD2 may be deficient in additional lipids. In the future, the researchers will use these mice to study how well dietary fatty acid supplements alleviate colitis symptoms and to explore how colonic SCD activity affects development of colorectal cancer.
“Certainly, these studies have high translational potential,” Duchamp wrote. “We are unaware of studies exploring the role of dietary MUFA supplementation in treating colitis symptoms and are excited to extend our work in the mouse model to such translational applications.

Details
Camille Duchamp will present this research from 5:30 to 6:30 p.m. CDT on Sunday, March 24, at 2024, the 91影库 and Molecular Biology annual meeting in San Antonio. Her poster is at Board 340.
Abstract title: A role for intestinal stearoyl-CoA desaturase in modulating acute colonic inflammation.
Enjoy reading 91影库Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from 91影库Today
Enter your email address, and we鈥檒l send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

Hope for a cure hangs on research
Amid drastic proposed cuts to biomedical research, rare disease families like Hailey Adkisson鈥檚 fight for survival and hope. Without funding, science can鈥檛 鈥渃atch up鈥 to help the patients who need it most.

Before we鈥檝e lost what we can鈥檛 rebuild: Hope for prion disease
Sonia Vallabh and Eric Minikel, a husband-and-wife team racing to cure prion disease, helped develop ION717, an antisense oligonucleotide treatment now in clinical trials. Their mission is personal 鈥 and just getting started.

Defeating deletions and duplications
Promising therapeutics for chromosome 15 rare neurodevelopmental disorders, including Angelman syndrome, Dup15q syndrome and Prader鈥揥illi syndrome.

Using 'nature鈥檚 mistakes' as a window into Lafora disease
After years of heartbreak, Lafora disease families are fueling glycogen storage research breakthroughs, helping develop therapies that may treat not only Lafora but other related neurological disorders.

Cracking cancer鈥檚 code through functional connections
A machine learning鈥揹erived protein cofunction network is transforming how scientists understand and uncover relationships between proteins in cancer.

Gaze into the proteomics crystal ball
The 15th International Symposium on Proteomics in the Life Sciences symposium will be held August 17鈥21 in Cambridge, Massachusetts.